New genetic drug validation paper out in Science Translation Medicine

Our new paper describes a collaborative effort with the Broad Institute, the University of Vermont and others to develop novel treatments for cryptosporidiosis. In this study we provide the first rigorous genetic validation of a drug target in Cryptosporidium by using CRISPR/Cas9 directed engineering of drug resistance. Check it out at Science Translational Medicine